Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Murat, Albayrak"'
Autor:
Tahir Darcın, Istemi Serın, Mehmet Can Ugur, Omer Ekinci, İpek Yönal Hindilerden, Seval Akpınar, Tuba Hacıbekiroglu, Sinan Demircioğlu, Emine Gulturk, Murat Albayrak, İsmet Aydoğdu, Mehmet Sinan Dal, Mehmet Hilmi Doğu, Sinem Namdaroğlu, Ali Dogan, Meliha Nalçacı, Burhan Turgut, Semih Başcı, Fevzi Altuntaş
Publikováno v:
Hitit Medical Journal, Vol 6, Iss 2, Pp 186-192 (2024)
Objective: We present data of patients with relapsed/ refractory T cell lymphomas treated with brentuximab vedotin (BV) in real-world practice. Material and Method: This study is an observational, multi-center, retrospective study. The data of patien
Externí odkaz:
https://doaj.org/article/9ca01e30518240fc9f0619b73350c36a
Autor:
Selim Sayın, Murat Yıldırım, Ahmet Kürşad Güneş, Merih Reis Aras, Esra Şafak Yılmaz, Murat Albayrak, Gülsüm Özet, Meltem Aylı
Publikováno v:
Gülhane Tıp Dergisi, Vol 66, Iss 1, Pp 43-48 (2024)
Aims:Lactate dehydrogenase (LDH) and platelet count are routinely used to evaluate response to treatment and discontinuation of treatment in thrombotic thrombocytopenic purpura (TTP). This study aimed to evaluate the mean platelet volume (MPV) and pl
Externí odkaz:
https://doaj.org/article/47de30a897a3422aa8f0b5b92140a89f
Autor:
Fatma Yılmaz, Bugra Saglam, Ufuk Gorduk, Ugur Kalan, Hacer Berna Afacan Öztürk, Ahmet Kursad Gunes, Murat Albayrak
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 16, Iss 1 (2024)
Introduction. Patients with leukaemia are exposed to infections as long as they are neutropenic. During this period, anorectal pathologies are among the common foci of infection with high mortality. We aimed in this study to investigate the factors t
Externí odkaz:
https://doaj.org/article/3ca76beb2ee045728e12e60fc9aa39cf
Autor:
Emine Merve Savaş, Seda Yılmaz, Ayşe Asena Başer Dikyar, Zübeyde Nur Özkurt, Ramazan Öcal, Ferda Can, Sezgin Pepeler, Lale Aydın Kaynar, Sanem Gökçen, Abdulkerim Yıldız, Murat Albayrak, Sema Karakuş, Özcan Çeneli, Münci Yağcı
Publikováno v:
Turkish Journal of Hematology, Vol 40, Iss 4, Pp 236-241 (2023)
Objective: The discovery of imatinib was a milestone for chronic myeloid leukemia (CML). As the life expectancy of CML patients has approached that of the general population, research has shifted towards improving quality of life and economic conside
Externí odkaz:
https://doaj.org/article/dba536e5bd394b3b8141212902e2496b
Does Systemic Immune Inflammation Index Predicts Survival In Diffuse Large B Cell Lymphoma Patients?
Autor:
Murat Albayrak, Ahmet Kürşad Güneş, Ümit Yavuz Malkan, Fatma Yılmaz, Hacer Berna Afacan Öztürk, Merih Reis Aras
Publikováno v:
Hitit Medical Journal, Vol 5, Iss 3, Pp 170-174 (2023)
Objective: The systemic immune inflammation index has been considered a novel prognostic biomarker in several malignant tumors. The aim of the current study was to determine the association between the systemic immune inflammation index and prognosis
Externí odkaz:
https://doaj.org/article/43b61cf9e6c64bdd9fe4f329215e5537
Autor:
İstemi Serin, Mehmet Hilmi Doğu, Ömer Ekinci, Gülsüm Akgün Çağlıyan, Abdulkadir Baştürk, Merih Reis Aras, Sinan Demircioğlu, Burhan Turgut, Mustafa Merter, Sibel Kabukçu Hacıoğlu, Metin Bağcı, Murat Albayrak, Serdal Korkmaz, Mehmet Ali Erkurt, Mehmet Sinan Dal, Fadime Ersoy Dursun, Anıl Tombak, İsmet Aydoğdu, Turgay Ulaş, Fevzi Altuntaş
Publikováno v:
İstanbul Medical Journal, Vol 24, Iss 2, Pp 120-125 (2023)
Introduction:Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV).Methods:A total of 34 patients wit
Externí odkaz:
https://doaj.org/article/2f9813f1062246cfa7c5bb2a592ed5f8
Autor:
Fatma YILMAZ, Murat ALBAYRAK, Abdulkerim YILDIZ, Hacer Berna AFACAN ÖZTÜRK, Senem MARAL, Ümit Yavuz MALKAN, Pınar AKYOL, Merih REİS ARAS, Buğra SAĞLAM, Mesut TIĞLIOĞLU
Publikováno v:
Ahi Evran Medical Journal, Vol 6, Iss 3, Pp 226-233 (2022)
Purpose: Coronavirus disease 2019 is a viral disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical and laboratory predictors may provide identification of patients at risk of mortality and guide treatment. This stud
Externí odkaz:
https://doaj.org/article/f82dcc849f63442a9e24b15068368e13
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss 1, Pp 131-133 (2023)
Externí odkaz:
https://doaj.org/article/52ed1b6a78e3494ea515973656233507
Autor:
Ümit Yavuz Malkan, Senem Maral, Fatma Yılmaz, Merih Reis Aras, Buğra Sağlam, Mesut Tığlıoğlu, Hacer Berna Afacan Öztürk, Murat Albayrak, Pınar Tığlıoğlu
Publikováno v:
Sağlık Akademisi Kastamonu, Vol 7, Iss Covid-19 Ek Sayısı, Pp 108-115 (2022)
Introduction Coronavirus disease 2019 (COVID-19) were declared as pandemic by World Health Organization. With this study, we aimed to define our patients who were followed up with malign or benign hematological diagnoses and diagnosed with COVID-19;
Externí odkaz:
https://doaj.org/article/64f1fa33e75d4cfebafd3c5791864f38
Autor:
Mesut Tığlıoğlu, Buğra Sağlam, Merih Reis Aras, Pınar Akyol, Senem Maral, Fatma Yılmaz, Hacer Berna Afacan Öztürk, Abdulkerim Yıldız, Murat Albayrak
Publikováno v:
Sağlık Akademisi Kastamonu, Vol 7, Iss Covid-19 Ek Sayısı, Pp 100-107 (2022)
Introduction Predictive parameters that can affect the course of this infection have been the main topic of research since the beginning of the COVID-19 (Coronavirus disease 2019) pandemic. Since the discovery of blood groups, the effect of these on
Externí odkaz:
https://doaj.org/article/606ddb9f24b1461880f055798a900a4f